Navigation Links
Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds
Date:11/27/2007

ate from its DARA program, Pharmacopeia's Phase 2 and Phase 1 clinical studies with respect to PS433540, including timing and expected outcomes of such studies, Pharmacopeia's plans to develop PS178990, a product candidate from its SARM program, Pharmacopeia's Phase 1 clinical studies with respect to PS178990, including timing and expected outcomes of such studies, Pharmacopeia's estimates of the market opportunities for its product candidates, including PS433540 and PS178990, Pharmacopeia's ability to successfully perform under its collaborations with Bristol-Myers Squibb, Cephalon, Organon and Wyeth, Pharmacopeia's ability to build its pipeline of novel drug candidates through its own internally-funded drug discovery programs, third party collaborations and in-licensing, Pharmacopeia's ability to raise additional capital, Pharmacopeia's anticipated operating results, financial condition, liquidity and capital resources, Pharmacopeia's expectations concerning the legal protections afforded by U.S. and international patent law, Pharmacopeia's ability to pursue the development of new compounds and other business matters without infringing the patent rights of others, additional competition, and changes in economic conditions.

Further information about these and other relevant risks and uncertainties may be found in Pharmacopeia's Reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Pharmacopeia urges you to carefully review and consider the disclosures found in its filings which are available in the SEC EDGAR database at http://www.sec.gov and from Pharmacopeia at http://www.pharmacopeia.com. All forward-looking statements in this press release and oral statements made with respect to information contained in this press release are qualified entirely by the cautionary statements included in this press release and such fil
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Pharmacopeia Announces Senior Additions to Management Team
2. Pharmacopeia Acquires Selective Androgen Receptor Modulator (SARM) Program from Bristol-Myers Squibb
3. GlaxoSmithKline Responds to JAMA Articles
4. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
5. Congressional Black Caucus Foundation and GlaxoSmithKline Announce Supplier Business Initiative Study Results
6. AUDIO from Medialink and GlaxoSmithKline: A New Nasal Spray for Allergy Relief
7. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline
8. GlaxoSmithKline Aids California Fire Relief Efforts
9. Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program
10. GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.
11. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... NEW YORK, NY (September 16, 2014) The ... received the 2014 Higher Education Excellence in Diversity ... oldest and largest diversity-focused publication in higher education. ... national honor recognizing U.S. colleges and universities that ... will be featured along with 82 other recipients ...
(Date:9/16/2014)... Orange, NJ. September 16, 2014. Kessler Foundation researchers ... slowed processing speed in the executive deficits found ... slowed processing speed account for executive deficits in ... neuroimaging," was published online ahead of print on ... The authors are Victoria Leavitt, PhD, of ...
(Date:9/16/2014)... judges are the unwitting focus of some of Australia,s ... to improve their performance in competition, thanks to a ... Dr Daniel Greenwood, from QUT,s Institute of Health and ... Sport Centre of Excellence for Applied Sport Science Research, ... such as cricket, long jump, triple jump and pole ...
(Date:9/16/2014)... San Francisco, September 15, 2014 For patients with ... and stereotactic ablative radiation (SABR) may be a ... surgery that may not otherwise be an option, ... Society for Radiation Oncology,s (ASTRO,s) 56th Annual Meeting. ... for individuals with pancreatic ductal adenocarcinoma (PDA), the ...
(Date:9/16/2014)... be presented at the ESMO 2014 Congress will be ... (CEST) to give you a first glimpse of what ... under the leading theme Precision Medicine in Cancer Care. ... therapy is now possible for an increasing number of ... towards a common goal --improved patient outcomes. This is ...
Breaking Medicine News(10 mins):Health News:Columbia University College of Dental Medicine receives diversity award 2Health News:Columbia University College of Dental Medicine receives diversity award 3Health News:Columbia University College of Dental Medicine receives diversity award 4Health News:Getting the jump on competitors: QUT study 2Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 2Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 3Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 4Health News:ESMO 2014 Congress Preview 2
... School of Medicine has helped confirm the reliability of ... individual's genetic makeup. ,The Stanford group was ... the genetic test can identify patients who are at ... infection. That means high-risk patients could be directed toward ...
... A report released by the Australian Institute of Health ... in Queensland. Nearly 20 to 50% of the population ... to be relying on anti-depressants heavily. ... affair in Queensland where nearly 11,500 prescriptions for anti ...
... today has become the number one killer. More so, related ... occupational Hazard// with millions of people running the risk of ... fibers and second hand smoker are the major causes of ... from exposure to benzene from the dye, drugs, pesticides and ...
... the world. There is also a rise of alcohol abuse ... women says that in women cognitive problems develop faster in ... subject to physical changes in the brain more rapidly than ... at the research institute RTI at the university in Baltimore ...
... Institute of Medicine released a report recommending nutrition ... school environment, such as a la carte cafeteria ... Dairy Council (NDC) applauds the overall recommendations outlined ... nonfat and low-fat dairy products, fruits, vegetables and ...
... An international research team, led by investigators from the ... Institute (DFCI), has found// a new way that some ... drugs like Iressa and Tarceva. Their report, which will ... online release, describes a totally new resistance mechanism that ...
Cached Medicine News:Health News:New Test Helps Identify Hepatitis C Patients at High Risk of Developing Cirrhosis 2Health News:New Test Helps Identify Hepatitis C Patients at High Risk of Developing Cirrhosis 3Health News:Today Cancer is the Deadliest Killer 2Health News:Alcoholism Develops Cognitive Problems in Women 2Health News:National Academy of Sciences' Institute of Medicine Report Calls for More Dairy Foods at School 2Health News:New Mechanism Identified for Resistance to Targeted Lung Cancer Drugs 2Health News:New Mechanism Identified for Resistance to Targeted Lung Cancer Drugs 3
(Date:9/16/2014)... 2014  DNAtrix, Inc., experts in oncolytic virus ... treated with the company,s lead product, DNX-2401, a ... randomized, multicenter, open-label Phase Ib study for patients ... with leading neurosurgeons and neuro-oncologists in the US, ... randomized Phase Ib study of DNX-2401 at Moffitt ...
(Date:9/16/2014)... 16, 2014  Eli Lilly and Company (NYSE: ... an agreement to co-develop and commercialize AZD3293, an ... in development as a potential treatment for Alzheimer,s ... is characterized by the accumulation of amyloid plaque ... with the development of beta-amyloid. Inhibiting BACE is ...
(Date:9/15/2014)... Sept. 16, 2014  Bayer HealthCare and Orion ... Finland , have begun to enroll ... an investigational oral androgen receptor inhibitor in clinical ... men with castration-resistant prostate cancer who have rising ... metastases. The trial is designed to determine the ...
Breaking Medicine Technology:DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 2Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 2Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 3Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 4Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 2Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 3
... Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced that ... at the Lazard Capital Markets 8th Annual Healthcare Conference, being ... Bentsur,s presentation is scheduled to take place on Wednesday, November ... audio webcast of Mr. Bentsur,s presentation will be accessible from ...
... 2011 Booth # 407 at The American ... NxStage® Medical, Inc. (Nasdaq: NXTM ), ... announced that its Medisystems division has won a ... Solution to Atlantic Dialysis Management Services centers. ...
Cached Medicine Technology:Keryx Biopharmaceuticals to Present at Lazard Capital Markets 8th Annual Healthcare Conference 2NxStage Awarded Multi-Year Contract to Supply Atlantic Dialysis Management Services with Vasc-Alert Access Surveillance Solution 2NxStage Awarded Multi-Year Contract to Supply Atlantic Dialysis Management Services with Vasc-Alert Access Surveillance Solution 3
... Innovations' Instrument Manager (IM) is an instrument ... system that enables laboratories to work more ... as a data management solution that stands ... information system, filling those important gaps in ...
... These color vision tests have been designed ... the type and estimating the grade of ... measure Red, Green, Blue, Yellow. They provide ... deficiencies. Screening is accomplished using the initial ...
... sets are designed to indicate color deficiency ... is used to separate Medium and Strong ... test is much more difficult and is ... Both of these tests provide basic ...
Single Use Loading Units with Titanium Staplers for use with MULTIFIRE ENDO TA™ 30 12 mm (Single Use Staplers with Titanium Staplers)....
Medicine Products: